Prestige Consumer Q3 revenue $282.7M (+2.6% YoY), raises FY EPS outlook to ~$4.33

Given the strong Q3 performance, we are raising our fiscal 2024 earnings outlook. We continue to anticipate revenues of $1,135 to $1,140 million, thanks to our diverse portfolio of brands. We expect this outlook to continue to translate into industry-leading free cash flow, which positions us to continue creating long-term shareholder value through stable organic growth and strategic capital allocation,” Mr. Lombardi concluded. Prior Fiscal 2024 Outlook Current Fiscal 2024 Outlook Revenue $1,135 to $1,140 million $1,135 to $1,140 million Organic Revenue Growth 1% to 2% 1% to 2% Diluted E.P.S. $4.27 to $4.32 Approximately $4.33 Free Cash Flow $240 million or more $240 million or more

Reported revenues for the first nine months of fiscal 2024 totaled $848.4 million, a 0.8% increase compared to revenues of $841.9 million for the first nine months of fiscal 2023. Revenues increased 1.2% versus the prior year nine-month period excluding the impact of foreign currency. The revenue growth for the first nine months was driven by solid International segment performance and strong Eye & Ear Care category sales in North America, partially offset by lower Women’s Health category sales and the strategic exit of private label revenues. Reported net income for the first nine months of fiscal 2024 totaled $159.9 million, an increase compared to the prior year comparable period net income of $158.2 million. Diluted earnings per share were $3.19 for the first nine months of fiscal 2024 increased compared to diluted earnings per share of $3.14 in the prior year comparable period.

Reported revenues in the third quarter of fiscal 2024 of $282.7 million compared to a $275.5 million in the third quarter of fiscal 2023. Revenues increased 2.6% versus the prior year third quarter on both a reported and organic basis. The revenue growth for the quarter was led by strong Eye & Ear Care category performance in North America and Hydralyte ® brand growth in the International segment, partially offset by an expected decline in the Cough & Cold category and the planned strategic exit of private label revenues. Reported net income for the third quarter of fiscal 2024 totaled $53.0 million, an increase versus the prior year third quarter’s net income of $52.0 million. Diluted earnings per share of $1.06 for the third quarter of fiscal 2024 increased 2.2% versus $1.04 in the prior year comparable period.